The most common mistake I see with sermorelin is not in the choice of peptide — it is in the protocol. Patients start at the wrong dose, inject at the wrong time of day, skip lab monitoring, or run it continuously until the pituitary stops responding as well as it should. A peptide that works by engaging the hypothalamic-pituitary axis needs to be used in a way that respects that axis.
This guide covers everything you need to run sermorelin correctly: starting dose, titration schedule, timing rationale, cycle structure, stacking doses, and how to interpret your IGF-1 results. For the underlying mechanism and clinical applications, see Sermorelin Peptide: A Physician’s Guide to Growth Hormone Optimization.
At a Glance
| Parameter | Guidance |
|---|---|
| Starting dose | 100–150 mcg subcutaneous, before bed |
| Titration step | 50 mcg per 4–6 weeks |
| Maintenance range | 200–300 mcg (most patients) |
| Maximum dose | 500 mcg/day (rarely needed; diminishing returns above 300 mcg) |
| Dosing frequency | Once daily (bedtime) standard; twice daily for advanced protocols |
| Cycle structure | 5 days on / 2 days off (weekly) OR 3 months on / 1 month off |
| Target IGF-1 | Upper quartile of age-adjusted reference range |
| Lab monitoring | Baseline, then every 6–8 weeks during titration; every 3–4 months maintenance |
| Route | Subcutaneous injection (abdomen, thigh, or lateral deltoid fat pad) |
Starting Dose: Why Lower Is Smarter
Sermorelin’s mechanism depends on the pituitary responding appropriately to a GHRH signal. Starting too high can cause transient side effects — flushing, water retention, joint aching — that patients wrongly attribute to the peptide rather than to an overly aggressive introduction.
Standard starting dose: 100 mcg subcutaneously before bed, five nights per week.
For older adults (over 65), women in early post-menopause, and patients with baseline low body weight, I begin at 100 mcg and hold that dose for 8 weeks before any titration. Pituitary somatotroph reserve declines with age, and the dose-response relationship is less predictable in this group.
For younger adults (35–55) with clearly documented GH decline and no complicating metabolic factors, 150 mcg is a reasonable starting point.
Do not begin at 200 mcg or higher regardless of body weight. The plateau of GH output per microgram of sermorelin is not linear — you are stimulating a biological process, not delivering a drug concentration that scales predictably with mass.
Titration Schedule
Titrate based on IGF-1 response, not symptoms. Subjective improvements (sleep quality, energy) often emerge before IGF-1 moves meaningfully. Use the blood work to guide dose escalation, not the feel-good effect.
General titration framework:
| Timepoint | Action |
|---|---|
| Baseline | Measure fasting IGF-1, fasting glucose, insulin |
| Week 4–6 | Measure IGF-1; if below target range, increase by 50 mcg |
| Week 8–12 | Measure IGF-1; adjust again if still below target |
| Week 16–20 | Most patients at stable maintenance dose |
| Ongoing | Check IGF-1 every 3–4 months |
Target IGF-1: Upper quartile of the age-adjusted reference range. Many labs report a wide range (e.g., 90–360 ng/mL for a 45-year-old). Aim for the upper portion — around 250–320 ng/mL for most middle-aged adults — not supraphysiologic values. An IGF-1 above the age-adjusted reference ceiling is a signal to reduce the dose, not celebrate an effect.
Sermorelin rarely pushes IGF-1 above the normal reference range at doses up to 300 mcg, which is one of its primary safety advantages over recombinant HGH. If a patient is consistently approaching the upper limit of normal on 200 mcg, that may be their maintenance dose — there is no clinical justification to escalate.
Timing: Why Bedtime Is Non-Negotiable
Growth hormone is not secreted evenly throughout the day. The dominant GH pulse occurs during the first cycle of slow-wave (N3) sleep, typically 60–90 minutes after sleep onset. This pulse is responsible for a disproportionate share of GH’s downstream effects on tissue repair, fat mobilisation, and IGF-1 generation.
Sermorelin’s purpose is to amplify this pulse, not to create a new one at an unphysiologic time. Injecting in the morning or midday misses the synchronized window, delivers the GHRH signal when somatostatin tone is higher, and produces a blunted GH response relative to what the same dose achieves at bedtime.
Practical timing: Inject 30–45 minutes before your intended sleep time. You should not eat for at least 2 hours before the injection. Insulin spike from a recent meal elevates somatostatin, which attenuates GH release — the same reason fasting-state IGF-1 labs are important.
Avoid: Eating carbohydrates within 90 minutes of injection. Alcohol within 3 hours (disrupts slow-wave sleep and GH pulsatility independently).
Twice-Daily Dosing: When and How
Standard sermorelin protocol is once nightly. Twice-daily dosing is used in two circumstances:
-
Inadequate IGF-1 response at 300 mcg nightly — rather than escalating to 400–500 mcg at a single dose, splitting into 150–200 mcg at bedtime and a second 100–150 mcg injection in the early morning (5–6 AM) can augment total daily GH output while maintaining physiologic pulse characteristics.
-
Post-injury or post-surgical recovery — where accelerated tissue repair is the primary goal, a morning dose timed to the natural cortisol peak (which does not oppose GH as strongly as midday somatostatin tone) can add a supplemental anabolic signal.
Twice-daily dosing is not recommended for long-term maintenance in patients without a specific indication. It is harder to sustain, adds injection burden, and the incremental IGF-1 gain over optimized once-nightly dosing is modest for most patients.
Cycle Structure: Preserving Pituitary Sensitivity
Continuous, uninterrupted sermorelin use for more than 3–4 months can reduce pituitary sensitivity to GHRH signalling — a form of receptor adaptation rather than true desensitisation. The effect is not dramatic, but IGF-1 values may plateau or drift slightly downward even without dose changes.
Two cycling strategies work in practice:
5-On / 2-Off Weekly Cycling
Inject Monday through Friday, take Saturday and Sunday off. This is the most common approach in my clinical practice. It is easy to sustain, minimises the total number of injections, and appears sufficient to prevent the adaptation plateau. Most patients’ IGF-1 remains stable for 6–12 months on this schedule without needing dose adjustments.
3-Month On / 1-Month Off
Run sermorelin continuously for 12 weeks (sometimes 16 weeks for slower responders), then take a full month off before resuming. This is preferred for patients with compliance challenges around the weekly two-day break, or those who notice that their response diminishes particularly quickly.
During the off month, IGF-1 will decline toward baseline. This is expected and represents the restoration of pituitary sensitivity you are seeking. IGF-1 typically returns to pre-treatment baseline within 3–6 weeks of stopping.
Sermorelin + Ipamorelin: Stacking Dosage
Combining sermorelin with ipamorelin — a ghrelin mimetic that acts via a different receptor pathway — produces synergistic GH pulse amplification. The combination generates approximately 2–5× greater GH pulse amplitude than either agent alone at equivalent individual doses.
Standard stacking protocol:
| Compound | Dose | Timing |
|---|---|---|
| Sermorelin | 100–200 mcg | Before bed |
| Ipamorelin | 100–200 mcg | Same injection (mixed in syringe) or separate injection same time |
When stacking, reduce the sermorelin dose slightly from what you would use as monotherapy. The synergy means 100 mcg sermorelin + 100 mcg ipamorelin often produces greater GH output than 300 mcg sermorelin alone.
Titrate the combination as a unit — increase by 50 mcg of each peptide per 4–6 weeks if IGF-1 remains below target. The titration ceiling for the combination is typically 200 mcg of each compound. Going higher usually reflects suboptimal timing or dietary factors rather than genuine dose inadequacy.
For a full comparison of stacking sermorelin with CJC-1295 variants versus ipamorelin, see Sermorelin vs CJC-1295: Which Growth Hormone Peptide Is Right for You?.
Age-Specific Dosing Considerations
Adults 35–50
This cohort typically shows the clearest dose-response and the most subjective benefit from sermorelin. The pituitary is still capable of robust GH pulsatility — the problem is declining GHRH signal output from the hypothalamus, which sermorelin directly corrects. Standard titration applies: start at 100–150 mcg, titrate to the upper quartile of the IGF-1 reference range, and expect meaningful response by week 8–12.
Adults 50–65
Pituitary somatotroph reserve begins to decline as a separate factor from hypothalamic GHRH output. The dose-response curve is less steep. Patients in this range may need higher doses (250–350 mcg) to achieve target IGF-1, or may benefit more from the sermorelin + ipamorelin combination, which engages both the GHRH and ghrelin receptor pathways.
Watch fasting glucose more carefully in this age group. Sermorelin modestly blunts insulin sensitivity — usually clinically insignificant — but pre-diabetic patients should have glucose and HbA1c monitored alongside IGF-1.
Adults Over 65
Starting dose: 100 mcg five nights per week. Hold this dose for at least 8 weeks and recheck IGF-1 before any titration. The risk of over-correction (IGF-1 pushed to the high end of normal, with attendant fluid retention, carpal tunnel symptoms, or joint discomfort) is higher in this cohort. Maintain IGF-1 in the middle rather than upper quartile of the age-adjusted range if these symptoms appear.
Women and Post-Menopausal Considerations
Women tend to have higher baseline GH pulsatility than men of equivalent age and lower volumes of distribution for peptides. Women may respond at lower doses than men — some achieve target IGF-1 at 100–150 mcg nightly without further escalation.
Post-menopausal women on oestrogen therapy should be aware that oral oestrogens (not transdermal) can reduce IGF-1 by upregulating hepatic clearance. If baseline IGF-1 is lower than expected and the patient is on oral oestrogen replacement, this is likely a contributor. Transdermal oestradiol does not carry the same effect.
For a broader discussion of peptide therapy in women, see Peptide Therapy for Women: A Physician’s Guide.
Lab Monitoring Panel
| Lab | Timing | Purpose |
|---|---|---|
| IGF-1 (fasting) | Baseline, every 6–8 weeks during titration, every 3 months maintenance | Primary efficacy marker |
| Fasting glucose | Baseline, every 3 months | Sermorelin modestly blunts insulin sensitivity |
| Fasting insulin / HOMA-IR | Baseline, 3 months | Metabolic safety |
| HbA1c | Baseline, every 6 months | Long-term glucose homeostasis |
| Cortisol (AM) | Baseline | Rule out cortisol excess as GH antagonist; relevant in fatigue workup |
| Total and free testosterone | Baseline | GH optimisation works best when sex hormones are also optimised |
| Thyroid panel (TSH, free T3, free T4) | Baseline | Hypothyroidism blunts GH response independently |
When to adjust based on IGF-1:
- IGF-1 below the lower tertile of age-adjusted range after 8 weeks at a given dose → increase by 50 mcg
- IGF-1 in the upper quartile but within reference range → maintain current dose
- IGF-1 at or above the reference ceiling → reduce dose by 50 mcg and recheck in 6 weeks
- IGF-1 above reference ceiling with symptoms (joint swelling, carpal tunnel, fluid retention) → hold sermorelin for 2 weeks, resume at lower dose
Side Effects and Dose-Related Tolerability
Sermorelin is well-tolerated at appropriate doses. Side effects are largely dose-related:
Injection site: Mild transient erythema or tenderness at the injection site is common and not a reason to stop. Rotate sites — abdomen (preferred), thigh, lateral upper arm. Use a 29–31 gauge ½-inch needle.
Flushing and warmth: Occurs in approximately 10–15% of patients after injection, typically lasting 5–15 minutes. Usually resolves with continued use. If persistent or distressing, reduce dose by 50 mcg.
Water retention: Mild puffiness, particularly around the ankles or face, usually indicates the dose is at or slightly above optimal. Reduce by 50 mcg; if it persists, check IGF-1.
Headache: Uncommon, usually transient after the first few injections. If persistent, evaluate for intracranial hypertension (rare but warrants investigation if headaches are severe or positional).
Drowsiness: Injection before bed is intentionally timed to coincide with, and reinforce, sleep onset. Some patients notice more rapid sleep onset, which is a desirable effect rather than a side effect.
Elevated fasting glucose: A modest rise (typically 5–10 mg/dL) is expected, mediated by GH-induced hepatic glucose output. Not clinically significant in most patients. Monitor in those with pre-diabetes or insulin resistance.
Related Articles
- Sermorelin Peptide: A Physician’s Guide to Growth Hormone Optimization — mechanism, clinical applications, and patient selection
- Sermorelin vs CJC-1295: Which Growth Hormone Peptide Is Right for You? — head-to-head comparison with CJC-1295, Mod GRF 1-29, and tesamorelin
- CJC-1295 + Ipamorelin: Dosage, Timing, and Stacking Protocol — dosage guide for the CJC-1295/ipamorelin combination
- Peptide Stacking Guide: Which Peptides to Combine and How — framework for multi-peptide protocols
- Peptide Therapy for Women: A Physician’s Guide — female-specific dosing and hormonal considerations
References
-
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308. doi:10.2147/ciia.2006.1.4.307
-
Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. doi:10.1016/s0026-0495(97)90174-2
-
Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GHF and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. doi:10.1210/jcem.75.2.1639953
-
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-0702
-
Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. doi:10.1210/edrv.19.6.0353
-
Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018;6(1):45-53. doi:10.1016/j.sxmr.2017.02.004
-
Kargi AY, Merriam GR. Diagnosis and treatment of growth hormone deficiency in adults. Nat Rev Endocrinol. 2013;9(6):335-345. doi:10.1038/nrendo.2013.77
